Swedish Orphan Biovitrum AB announced that Geoffrey McDonough will leave the company on July 1, 2017, and that a search for a new Chief Executive Officer has been initiated to identify his successor. Under his leadership the company has become a prominent rare disease biotech company with a vibrant and growing commercial portfolio and significant growth potential ahead.